Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Better Buy: Merck vs Pfizer Stock

Its a big pharma showdown as health care analyst David Williamson discusses whether Merck (NYSE: MRK) or Pfizer (NYSE: PFE) is the better buy. Both stocks have a lot going for them, Merck an exciting pipeline featuring a likely first to market immuno-oncology drug, a hepatitus-c cure, and even a potential treatment for Alzheimer's. Pfizer has a sizable cash horde and an aggressive management team. While losing out on the lower taxes an AstraZeneca deal would have brought, shareholders can look forward to buybacks dividends and a possible huge expansion of its pneumonia vaccine.

Watch and find out in this episode of Market Check-Up, the Motley Fool's health care focused investing show which of these two stocks is the winner.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3003490, ~/Articles/ArticleHandler.aspx, 8/31/2015 4:12:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,536.31 -106.70 -0.64%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,777.00 -51.33 -1.06%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:56 PM
AZN $31.33 Down -0.34 -1.07%
AstraZeneca plc (A… CAPS Rating: ****
BMY $59.55 Down -1.06 -1.75%
Bristol-Myers Squi… CAPS Rating: ****
GILD $104.97 Down -2.81 -2.61%
Gilead Sciences CAPS Rating: *****
MRK $53.92 Down -1.45 -2.62%
Merck & Co., Inc. CAPS Rating: ****
PFE $32.20 Down -0.46 -1.40%
Pfizer CAPS Rating: ****